全文获取类型
收费全文 | 219篇 |
免费 | 18篇 |
国内免费 | 1篇 |
专业分类
儿科学 | 2篇 |
妇产科学 | 1篇 |
基础医学 | 14篇 |
临床医学 | 12篇 |
内科学 | 14篇 |
皮肤病学 | 1篇 |
神经病学 | 19篇 |
特种医学 | 2篇 |
外科学 | 8篇 |
综合类 | 2篇 |
预防医学 | 53篇 |
眼科学 | 1篇 |
药学 | 97篇 |
中国医学 | 7篇 |
肿瘤学 | 5篇 |
出版年
2023年 | 3篇 |
2022年 | 9篇 |
2021年 | 12篇 |
2020年 | 13篇 |
2019年 | 12篇 |
2018年 | 14篇 |
2017年 | 10篇 |
2016年 | 7篇 |
2015年 | 5篇 |
2014年 | 15篇 |
2013年 | 30篇 |
2012年 | 12篇 |
2011年 | 13篇 |
2010年 | 11篇 |
2009年 | 15篇 |
2008年 | 12篇 |
2007年 | 13篇 |
2006年 | 7篇 |
2005年 | 5篇 |
2004年 | 3篇 |
2003年 | 7篇 |
2002年 | 1篇 |
2001年 | 2篇 |
2000年 | 2篇 |
1999年 | 2篇 |
1998年 | 1篇 |
1993年 | 1篇 |
1982年 | 1篇 |
排序方式: 共有238条查询结果,搜索用时 15 毫秒
1.
《Seminars in perinatology》2022,46(7):151635
The Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network (NRN) maintains a database of extremely preterm infants known as the Generic Database (GDB). Begun in 1987, this database now includes more than 91,000 infants, most of whom are extremely preterm (<29 weeks gestation). The GDB has been the backbone of the NRN, providing high quality, prospectively collected data to study the changing epidemiology of extreme prematurity and its outcomes over time. In addition, GDB data have been used to generate hypotheses for prospective studies and to develop new clinical trials by providing information about the numbers and characteristics of available subjects and the expected event rates for conditions and complications to be studied. Since its inception, the GDB has been the basis of more than 200 publications in peer-reviewed journals, many of which have had a significant impact on the field of neonatology. 相似文献
2.
Charanpreet Singh Nishant Jindal Padma Youron Pankaj Malhotra Gaurav Prakash Alka Khadwal Arihant Jain Sreejesh Sreedharanunni Man Updesh Singh Sachdeva Shano Naseem Neelam Varma Subhash Varma Deepesh P. Lad 《Indian journal of hematology & blood transfusion》2021,37(2):313
To report the efficacy, safety, and quality of life (QoL) on generic and innovator ibrutinib in Indian CLL patients. This was a single centre, prospective study of treatment-naive (TN), and relapsed/refractory (R/R) CLL patients receiving ibrutinib in India. The choice of innovator or generic ibrutinib was as per patient discretion. Response and adverse events were recorded as per the 2018 iwCLL guidelines and CTCAEv4.0. QoL was assessed using the EORTC QLQ-C30 and CLL17 questionnaires. A total of 32 CLL patients (TN, n = 7 and R/R, n = 25) received ibrutinib from 2016–2019. The median age was 60 years (37–84). All TN patients attained partial response without any grade 3/4 adverse events (AE). Ibrutinib was less tolerated in the R/R setting, with 52% patients developing grade 3/4 AE and required dose reduction. Eleven patients (44%) died during follow-up. Grade 3–5 infections were seen in 44% of R/R CLL patients. Generic ibrutinib (n = 8) was comparable to innovator ibrutinib (n = 17) in terms of efficacy, safety, and QoL. Ibrutinib is less well tolerated in Indian R/R CLL patients. Infections are a common cause of morbidity and mortality. This study affirms the safety and efficacy of generic ibrutinib.Electronic supplementary materialThe online version of this article (10.1007/s12288-020-01378-6) contains supplementary material, which is available to authorized users. 相似文献
3.
目的评价左乙拉西坦的国产仿制药替换原研药进口左乙拉西坦治疗儿童癫痫的疗效及安全性。方法回顾性分析2019年5月至2020年12月在广东省人民医院住院或门诊接受左乙拉西坦的国产仿制药替换治疗的154例癫痫患儿的临床资料,分析比较左乙拉西坦的国产仿制药替换原研药治疗的效果及安全性。结果154例患儿基线期癫痫控制率为77.3%(119/154),替换治疗6个月后癫痫控制率达83.8%(129/154),差异有统计学意义(P<0.05)。基线期与替换治疗6个月后癫痫发作频率比较差异无统计学意义(P>0.05)。替换治疗后无效患儿出现难治性癫痫比例高于有效患儿(P<0.05)。替换治疗前,仅1例患儿(0.6%)出现嗜睡;替换治疗后,3例患儿(1.9%)观察到轻度药物不良反应,包括头晕、嗜睡、易激惹、脾气暴躁,与替换治疗前比较差异无统计学意义(P>0.05)。结论左乙拉西坦的国产仿制药替换原研药进口左乙拉西坦治疗儿童癫痫是安全有效的,值得推广,但是需要更多的前瞻性随机对照试验来证实。 相似文献
4.
Pamela P. Pei Milton C. Weinstein X. Cynthia Li Michael D. Hughes A. David Paltiel Taige Hou 《HIV clinical trials》2015,16(6):207-218
Value of Information (VOI) analysis examines whether to acquire information before making a decision. We introduced VOI to the HIV audience, using the example of generic antiretroviral therapy (ART) in the US.Methods and Findings:We used a mathematical model and probabilistic sensitivity analysis (PSA) to generate probability distributions of survival (in quality-adjusted life years, QALYs) and cost for three potential first-line ART regimens: three-pill generic, two-pill generic, and single-pill branded. These served as input for a comparison of two hypothetical two-arm trials: three-pill generic versus single-pill branded; and two-pill generic versus single-pill branded. We modeled pre-trial uncertainty by defining probability distributions around key inputs, including 24-week HIV-RNA suppression and subsequent ART failure. We assumed that, without a trial, patients received the single-pill branded strategy. Post-trial, we assumed that patients received the most cost-effective strategy. For both trials, we quantified the probability of changing to a generic-based regimen upon trial completion and the expected VOI in terms of improved health outcomes and costs. Assuming a willingness to pay (WTP) threshold of $100?000/QALY, the three-pill trial led to more treatment changes (84%) than the two-pill trial (78%). Estimated VOI was $48?000 (three-pill trial) and $35?700 (two-pill trial) per future patient initiating ART.Conclusions:A three-pill trial of generic ART is more likely to lead to post-trial treatment changes and to provide more value than a two-pill trial if policy decisions are based on cost-effectiveness. Value of Information analysis can identify trials likely to confer the greatest impact and value for HIV care. 相似文献
5.
《Health policy (Amsterdam, Netherlands)》2015,119(5):612-619
ObjectivesThis study aimed to explore the predictors of the selection between brand name drug (BR) and generic drug (GE) and to clarify the quantitative relationship about selection.MethodsWe identified “incident users” who dispensed statins between April 2008 and June 2011 in commercially databases consisted of dispensing claims databases (DCD) of out-of-hospital pharmacies and hospital claims databases (HCD) of in-house pharmacies in Japan. Predictors of the selection between BR and GE, including price difference (PD), the price of BR, their interaction and percent change of the price of GE relative to BR were explored by logistic regression using DCD and HCD separately.ResultsWe extracted records of 670 patients who have opportunity for selection both BR and GE. Logistic regression analysis demonstrated that PD, the price of BR, interaction between them, and prescriber affiliation were factors significantly associated with the selection in the DCD; logit (p) = 9.735 − 0.251 × PD − 0.071 × the price of BR + 0.002 × PD × the price of BR − 1.816 × affiliation + 0.220 × gender − 0.008 × age + 0.038 × monthly medical fee. PD was inversely proportional to BR choice in DCD and lead to the opposite result in HCD. Numerical simulation of selection revealed that the quantitative relationships heavily depend on situations.ConclusionsPD and the price of BR are predictors of the selection between BR and GE interactively in out-of-hospital pharmacies, but not in in-house pharmacies of medical facilities. Results may support policies which increase the power of out-of-hospital pharmacies for selection. 相似文献
6.
7.
8.
9.
Mohamed Azmi Hassali Zhi Yen Wong Alian A. Alrasheedy Fahad Saleem Abdul Haniff Mohamad Yahaya Hisham Aljadhey 《Health policy (Amsterdam, Netherlands)》2014
Objectives
This review was conducted to document published literature related to physicians’ knowledge, attitudes, and perceptions of generic medicines in low- and middle-income countries (LMICs) and to compare the findings with high-income countries.Methods
A systematic search of articles published in peer-reviewed journals from January 2001 to February 2013 was performed. The search comprised nine electronic databases. The search strategy involved using Boolean operators for combinations of the following terms: generic medicines, generic medications, generic drugs, generic, generic substitution, generic prescribing, international non-proprietary, prescribers, doctors, general practitioners, physicians, and specialists.Results
Sixteen articles were included in this review. The majority (n = 11) were from high income countries and five from LMICs. The main difference between high income countries and LMICs is that physicians from high income countries generally have positive views whereas those from LMICs tend to have mixed views regarding generic medicines. Few similarities were identified among different country income groups namely low level of physicians’ knowledge of the basis of bioequivalence testing, cost of generic medicines as an encouraging factor for generic medicine prescribing, physicians’ concerns towards safety and quality of generic medicines and effect of pharmaceutical sales representative on generic medicine prescribing.Conclusion
The present literature review revealed that physicians from LMICs tend to have mixed views regarding generic medicines. This may be due to differences in the health care system and pharmaceutical funding system, medicine policies, the level of educational interventions, and drug information sources in countries of different income levels. 相似文献10.
Rie Shinoda Yasutaka Shinoda Kengo Ohashi Tomoko Matsuoka Tatsuya Hirose Tadashi Sugiyama Tomoaki Yoshimura 《Journal of infection and chemotherapy》2019,25(7):563-566
Teicoplanin formulations are marketed as antibiotic mixtures with several compounds that share the same core structure. Recent studies conducted in vitro have reported differences in the composition ratio of different teicoplanin products. In this retrospective study, we examined the trough blood concentration of the originator brand and a generic teicoplanin product. Target patients were retrospectively assigned to the originator (Targocid) or generic group. The groups were matched 1:1 using propensity scores. The initial trough blood concentration analysis identified 44 matches. In both groups, the median dosing day for the first measurements was 4, respectively. The initial trough blood concentration of the originator group was significantly higher (mean ± SD, 16.3 ± 4.5 mg/L) than that of the generic group (12.8 ± 4.7 mg/L; 95% CI, ?5.4 to ?1.6). A significant difference was observed in the frequency of serum creatinine elevation in the study of the frequency of adverse events using Common Terminology Criteria for Adverse Events (originator group, 41.9% vs generic group, 20.9%). In cases where discontinuation was necessary due to side effects, there were three patients in the originator group and one patient in the generic group. This study found that trough blood concentration differed between formulations. Therefore, correction might be necessary while monitoring drug concentration in the blood. Trough blood concentrations are used as surrogate markers for efficacy and safety, so further studies on differences in efficacy and safety between formulations are required. 相似文献